Acrobiosystems for English
icon_bulk_orderBulk inquiry/Quick order
There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > CD34


Brief Information

Name:Hematopoietic progenitor cell antigen CD34
Target Synonym:CD34,CD34 Molecule,CD34 Antigen,Hematopoietic Progenitor Cell Antigen CD34,Antigens, CD34
Number of Launched Drugs:1
Number of Drugs in Clinical Trials:13
Lastest Research Phase:Approved

Product ListCompare or Buy

By Product Status:
By Product Category:
By Species:
Cat. No. Species Product Description Structure Purity Feature
CD4-H82E3 Human Biotinylated Human CD34 Protein, His,Avitag™ (MALS verified)
CD4-H52H9 Human Human CD34 Protein, His Tag
ACRO Quality

Part of Bioactivity data

The purity of Biotinylated Human CD34 Protein, His,Avitag (Cat. No. CD4-H82E3) is more than 90% and the molecular weight of this protein is around 55-75 kDa verified by SEC-MALS.

Synonym Name



CD34 molecule is a cluster of differentiation molecule present on certain cells within the human body. It is a cell surface glycoprotein and functions as a cell-cell adhesion factor. It may also mediate the attachment of stem cells to bone marrow extracellular matrix or directly to stromal cells. As a ~ 110 kDa monomeric cell surface antigen, CD34 is highly glycosylated with nine potential N-linked and numerous potential O-linked glycosylation sites in its extracellular domain. The CD34 protein is a member of a family of single-pass transmembrane sialomucin proteins that show expression on early hematopoietic and vascular-associated tissue. CD34 is also an important adhesion molecule and is required for T cells to enter lymph nodes. It is expressed on lymph node endothelia whereas the L-selectin to which it binds is on the T cell. It was indicated that CD34 is a phosphorylation target for activated PKC, and couples to the hematopoietic adapter protein CrkL, which were involved in CD34 signaling pathways. CD34 is abberantly expressed in many kinds of tumors and is implicated in leukemogenesis.

Clinical and Translational Updates

Public Drug Information

Name Research Code Research Phase Company First Brand Name First Approved Country First Indication First Approved Company First Approved Date Indications Clinical Trials
Anti-CD34 mab-sirolimus (OrbusNeich) Approved Orbusneich Coronary Restenosis Orbusneich 2013-01-01 Coronary Artery Disease; Coronary Restenosis Details

Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
CLBS-12 CLBS-12 Phase 2 Clinical Caladrius Biosciences Inc Atherosclerosis; Thromboangiitis Obliterans; Ischemia Details
Retroviral ADA-transduced CD34+ cells (NHGRI/UCLA) Phase 2 Clinical Ucla Biomedical Library Adenosine deaminase deficiency Details
CD34+ bone marrow stem cells (University of California) Phase 2 Clinical The University Of California Davis Retinitis Pigmentosa; Diabetic Retinopathy; Macular Degeneration; Retinal Vein Occlusion Details
GSK-2696277 GSK-2696277; OTL-300 Phase 2 Clinical Glaxosmithkline Plc, Ospedale San Raffaele, Fondazione Telethon beta-Thalassemia Details
Autologous peripheral blood stem cell therapy (CellProthera) Phase 2 Clinical Cellprothera Myocardial Infarction Details
CD34 stem cell therapy (LA Childrens Hospital) Phase 2 Clinical Children'S Hospital Of Los Angeles HIV Infections; Heart Failure Details
Stem cell therapeutics (ExCellThera) ECT-002; ECT-003; ECT-005; UM171 + UM092; UM171 + UM390 Phase 2 Clinical Excellthera Inc Hematologic Neoplasms; Multiple Myeloma; Leukemia, Myeloid, Acute Details
Lentiviral vector transduced CD34+ cells Therapy Phase 2 Clinical Great Ormond Street Hospital For Children Nhs Foundation Trust Granulomatous Disease, Chronic Details
Cord blood stem cells(Tatcitus Therapeutics/Mount Sinai Health System) HSC-100 Phase 1 Clinical Icahn School Of Medicine At Mount Sinai, Tatcitus Therapeutics Hematologic Neoplasms; Leukemia; Hodgkin Disease; Myelodysplastic Syndromes; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Non-Hodgkin Details
shRNA-Modified CD34 Cell Therapy KL-AI20 Phase 1 Clinical Kanglin Biotech (Hangzhou) Co Ltd HIV Infections Details
Alpha-galactosidase A stem cell therapy (University Health Network/Ozmosis) Phase 1 Clinical University Health Network Fabry Disease Details
Autologous CD34+ Cells Therapy(Genmedicn) GMCN-508A Phase 1 Clinical Zhongji Zhiyao (Nanjing) Biotechnology Co Ltd, First Affiliated Hospital Of Guangxi Medical University alpha-Thalassemia Details
Donor-derived CD34+ HSC with CRISPR/Cas9-mediated CD33 deletion(German Cancer Research Center) Phase 1 Clinical German Cancer Research Center (Dkfz) Leukemia, Myeloid, Acute Details

This web search service is supported by Google Inc.

Call us
Call us
North America:
+1 800-810-0816 (Toll Free)
Asia & Pacific:
+86 400-682-2521
+1 888-377-6111
1 Innovation Way, Newark, DE 19711, USA

Leave a message